{
  "ticker": "BOT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967026",
  "id": "02967026",
  "pages": 24,
  "price_sensitive": false,
  "date": "20250708",
  "time": "0830",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250708/pdf/06lkxdtxhvn166.pdf",
  "summary": "### Summary of Material Information:  \n\n- **Sofdra\u2122 Launch Performance**:  \n  - **Gross Sales**: ~AUD $25 million cumulative (Jan-Jun 2025), with monthly growth.  \n  - **Prescriptions**: Over 16,000 TRx filled since launch (Feb 2025).  \n  - **Prescriber Base**: 2,300+ unique prescribers in June 2025 (up from 540 in Feb 2025).  \n  - **Refill Rates**: Exceeding industry average (3.4 fills per patient vs. 2 fills benchmark).  \n\n- **Gross-to-Net (GTN) Dynamics**:  \n  - GTN yield improved to **23%** (June 2025), target **30\u201340%**.  \n  - Fully reimbursed claims grew **50%** since launch; high-deductible claims declined **75%**.  \n\n- **Commercial Strategy**:  \n  - **Sales Force Expansion**: From 27 reps (Q3 2025) to **50 reps** (Q2 2026).  \n  - **Demand Drivers**: HCP engagement, digital/media campaigns, peer-reviewed data (JAAD publication).  \n\n- **Benchmark Comparison**:  \n  - Rep productivity (~AUD $81k net revenue/rep) exceeds early-stage peers (e.g., ZORYVE at ~USD $30k/rep).  \n\n*No material capital raising, financial results, or trading halt details identified.*",
  "usage": {
    "prompt_tokens": 5517,
    "completion_tokens": 308,
    "total_tokens": 5825,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-07T22:37:24.190139"
}